Long-term effects of tibolone on ocular functions in postmenopausal women

Archives of Gynecology and Obstetrics

Volumn 275, Issue 4, 2007, Pages 255-261

  Verit, Fatma Ferda ^a   Oguz, Halit ^a   Ozkul, Yasar ^a   Bozkurt, Omer ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

Ocular functions; Postmenopause; Tibolone

Indexed keywords

TIBOLONE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTRORETINOGRAPHY; EVOKED VISUAL RESPONSE; EYE EXAMINATION; FEMALE; HUMAN; INTRAOCULAR PRESSURE; LACRIMATION; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; STATISTICAL SIGNIFICANCE; TEAR FILM; TREATMENT DURATION; TREATMENT OUTCOME; VISION; VISUAL ACUITY; VISUAL FIELD;

ELECTRORETINOGRAPHY; ESTROGEN RECEPTOR MODULATORS; EVOKED POTENTIALS, VISUAL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; NORPREGNENES; POSTMENOPAUSE; VISION SCREENING; VISUAL FIELDS;

EID: 33847220035     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-006-0251-y     Document Type: Article

References (49)

1. Affinito P, Di Spiezio Sardo A, Di Carlo C, Sammartino A, Tommaselli GA, Bifulco G, Loffredo A, Loffredo M, Nappi C (2003) Effects of hormone replacement therapy on ocular function in postmenopause. Menopause 10:482-487
2. Abramov Y, Borik S, Yahalom C, Fatum M, Avgil G, Brzezinski A, Banin E (2005) Does postmenopausal hormone replacement therapy affect intraocular pressure? J Glaucoma 14:271-275
3. Albertazzi P, Di Micco R, Zanardi E (1998) Tibolone: a review. Maturitas 30:295-305
4. Altintas O, Caglar Y, Yuksel N, Demirci A, Karabas L (2004) The effects of menopause and hormone replacement therapy on quality and quantity of tear, intraocular pressure and ocular blood flow. Ophthalmologica 218:120-129
5. Bigsby RM, Cardenas H, Caperell-Grant A, Grubbs CJ (1999) Protective effects of estrogen in a rat model of age-related cataracts. Proc Natl Acad Sci USA 96:9328-9332
6. Bui BV, Fortune B (2004) Ganglion cell contributions to the rat full-Weld electroretinogram. J Physiol 555:153-173
7. Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, Panoulis KP, Kelekis DA, Creatsas GC (2002) Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause 9:110-116
8. Davis VL, Chan CC, Schoen TJ, Couse JF, Chader GJ, Korach KS (2002) An estrogen receptor repressor induces cataract formation in transgenic mice. Proc Natl Acad Sci USA 99:9427-9432
9. Doren M, Ruebig A, Holzgreve W (2001) Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril 75:554-558
10. Ederveen AG, Kloosterboer HJ (2001) Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. J Bone Miner Res 16:1651-1657
11. Eisner A, Austin DF, Samples JR (2004) Short wavelength automated perimetry and tamoxifen use. Br J Ophthalmol 88:125-130
12. Fuchsjager-Mayrl G, Nepp J, Schneeberger C, Sator M, Dietrich W, Wedrich A, Huber J, Tschugguel W (2002) Identification of estrogen and progesterone receptor mRNA expression in the conjunctiva of premenopausal women. Invest Ophthalmol Vis Sci 43:2841-2844
13. Genazzani A, Benedek-Jaszmann DM, Andolsek L, Kicovic PM, Tax L (1991) Org OD 14 and the endometrium. Maturitas 13:243-251
14. Guaschino S, Grimaldi E, Sartore A, Mugittu R, Mangino F, Bortoli P, Pensiero S, Vinciguerra A, Perissutti P (2003) Visual function in menopause: the role of hormone replacement therapy. Menopause 10:53-57
15. Gupta PD, Johar K, Nagpal K, Vasavada AR (2005) Sex hormone receptors in the human eye. Surv Ophthalmol 50:274-284
16. Hales AM, Chamberlain CG, Murphy CR, McAvoy JW (1997) Estrogen protects lenses against cataract induced by transforming growth factor-beta (TGFbeta). J Exp Med 185:273-280
17. Hammar M, Christau J, Rud T, Garre K (1998) A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 105:904-911
18. Hankins MW, Jones RJM, Ruddock KH (1998) Diurnal variation in the b-wave implicit time of the human electroretinogram. Vis Neurosci 15:55-67
19. International Standardization Committee (1989) Standard for clinical electroretinography. Arch Ophthalmol 107:816-819
20. Johnson CA, Adams AJ, Casson EJ, Brandt JD (1993) Blue-onyellow perimetry can predict the development of glaucomatous visual Weld loss. Arch Ophthalmol 111:645-650
21. Johnson CA, Adams AJ, Casson EJ, Brandt JD (1993) Progression of early glaucomatous visual Weld loss as detected by blue on-yellow and standard white-on-white automated perimetry. Arch Ophthalmol 111:651-656
22. Kloosterboer HJ (2001) Tibolone: a steroid with a tissue-specific mode of action. Steroid Biochem Mol Biol 76:231-238
23. Kuscu NK, Toprak AB, Vatansever S, Koyuncu FM, Guler C (2003) Tear function changes of postmenopausal women in response to hormone replacement therapy. Maturitas 44:63-68
24. Lacin S, Oruc S, Karaca S, Kuscu K, Koyuncu F, Uyar Y, Caglar H (2001) Assessment of the effectiveness of postmenopausal tibolone therapy on neural functions by measuring visual evoked potentials: a placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 98:72-76
25. Lange C, Fernandez J, Shim D, Spurr-Michaud S, Tisdale A, Gipson IK (2003) Mucin gene expression is not regulated by estrogen and/or progesterone in the ocular surface epithelia of mice. Exp Eye Res 77:59-68
26. Lee SM, Tseng LM, Li AF, Liu HC, Liu TY, Chi CW (2004) Polymorphism of estrogen metabolism genes and cataract. Med Hypotheses 63:494-497
27. Lundstrom E, Christow A, Kersemaekers W, Svane G, Azavedo E, Soderqvist G, Mol-Arts M, Barkfeldt J, von Schoultz B (2002) Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 186:717-722
28. McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR (1998) The epidemiology of dry eye in Melbourne, Australia. Ophthalmology 105:1114-1119
29. Modelska K, Cummings S (2002) Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 87:16-23
30. Moore RA (1999) Livial: a review of clinical studies. Br J Obstet Gynaecol 106:1-21
31. Moss SE, Klein R, Klein BE (2000) Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol 118:1264-1268
32. Nathorst-Boos J, Hammar M (1997) Effect on sexual life - a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas 26:15-20
33. Nonaka A, Kiryu J, Tsujikawa A, Yamashiro K, Miyamoto K, Nishiwaki H, Mandai M, Honda Y, Ogura Y (2000) Administration of 17beta-estradiol attenuates retinal ischemia-reperfusion injury in rats. Invest Ophthalmol Vis Sci 41:2689-2696
34. Paganini-Hill A, Clark LJ (2000) Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 60:167-172
35. Parisi P, Tommasini P, Piazza G, Manfredi M (2004) Scotopic threshold response changes after vigabatrin therapy in a child without visual Weld defects: a new electroretinographic marker of early damage? Neurobiol Dis 15(3):573-579
36. Sample PA, Weinreb RN (1990) Color perimetry for assessment of primary open-angle glaucoma. Invest Ophthalmol Vis Sci 31:1869-1875
37. Sator MO, Akramian J, Joura EA, Nessmann A, Wedrich A, Gruber D, Metka M, Huber JC (1998) Reduction of intraocular pressure in a glaucoma patient undergoing hormone replacement therapy. Maturitas 29:93-95
38. Sauve Y, Lu B, Lund RD (2004) The relationship between full Weld electroretinogram and perimetry-like visual thresholds in RCS rats during photoreceptor degeneration and rescue by cell transplants. Vis Res 44(1):9-18
39. Schaumberg DA, Buring JE, Sullivan DA, Dana MR (2001) Hormone replacement therapy and dry eye syndrome. JAMA 286:2114-2119
40. Schwarz M, Block F (1994) Visual and somatosensory evoked potentials are mediated by excitatory amino acid receptors in the thalamus. Electroencephalogr Clin Neurophysiol 91:392-398
41. Sendag F, Terek MC, Ozsener S, Oztekin K (2001) Mammo-graphic density changes in postmenopausal women using tibolone therapy. Int J Gynaecol Obstet 74:63-64
42. Sullivan DA, Wickham LA, Rocha EM, Kelleher RS, da Silveira LA, Toda I (1998) Influence of gender, sex steroid hormones, and the hypothalamic-pituitary axis on the structure and function of the lacrimal gland. Adv Exp Med Biol 438:11-42
43. Taner P, Akarsu C, Atasoy P, Bayram M, Ergin A (2004) The effects of hormone replacement therapy on ocular surface and tear function tests in postmenopausal women. Ophthalmologica 218:257-259
44. Toker E, Yenice O, Temel A (2003) Influence of serum levels of sex hormones on intraocular pressure in menopausal women. J Glaucoma 12:436-440
45. Ugurlu S, Hoffman D, Garway-Heath DF, Caprioli J (2000) Relationship between structural abnormalities and short-wavelength perimetric defects in eyes at risk of glaucoma. Am J Ophthalmol 129:592-598
46. Wachtmeister L (1998) Oscillatory potentials in the retina: what do they reveal. Prog Retin Eye Res 17:485-521
47. Yilmaz H, Erkin EF, Mavioglu H, Sungurtekin U (1998) Changes in pattern reversal evoked potentials during menstrual cycle. Int Ophthalmol 22(1):27-30
48. Yilmaz H, Erkin E, Mavioglu H, Lacin S (2000) Effects of oestrogen replacement therapy on pattern reversal visual evoked potentials. Eur J Neurol 7:217-221
49. Yucel I, Akar ME, Dora B, Akar Y, Taskin O, Ozer HO (2005) Effect of the menstrual cycle on standard achromatic and blue-on-yellow visual Weld analysis of women with migraine. Can J Ophthalmol 40:51-57